Vaccines have measurable efficacy obtained first from vaccine trials. However, vaccine efficacy (VE) is not a static measure and long-term population studies are needed to evaluate its performance and impact. COVID-19 vaccines have been developed in record time and the currently licensed vaccines are extremely effective against severe disease with higher VE after the full immunization schedule. To assess the impact of the initial phase of the COVID-19 vaccination rollout programmes, we used an extended Susceptible - Hospitalized - Asymptomatic/mild - Recovered () model. Vaccination models were proposed to evaluate different vaccine types: vaccine type 1 which protects against severe disease only but fails to block disease transmission, and vaccine type 2 which protects against both severe disease and infection. VE was assumed as reported by the vaccine trials incorporating the difference in efficacy between one and two doses of vaccine administration. We described the performance of the vaccine in reducing hospitalizations during a momentary scenario in the Basque Country, Spain. With a population in a mixed vaccination setting, our results have shown that reductions in hospitalized COVID-19 cases were observed five months after the vaccination rollout started, from May to June 2021. Specifically in June, a good agreement between modelling simulation and empirical data was well pronounced.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998287 | PMC |
| http://dx.doi.org/10.1016/j.idm.2023.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Initial Effectiveness of mRNA-1273 Against SARS-CoV-2 Infection and Hospitalization in Young Children.
Open Forum Infect Dis
January 2025
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Background: Data on mRNA-1273 (Moderna) vaccine effectiveness (VE) in children aged 6 months to 5 years are limited. The objectives of this study were to assess mRNA-1273 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19)-related hospitalization among children aged 6 months to 5 years during the initial 5 months of the vaccination campaign rollout, as well as to determine whether VE varied by age group (6 months to <2 years vs 2 to 5 years).
Methods: We used a test-negative study with linked health administrative data in Ontario, Canada, to evaluate vaccine effectiveness of mRNA-1273 against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization from July 28 to December 31, 2022.
Awareness, Acceptability and Factors Influencing Malaria Vaccine Uptake Among Caregivers of Children Under 5 in South-Western Nigeria.
Child Care Health Dev
January 2025
Statistics Programme, Bowen University, Iwo, Osun State, Nigeria.
Background: Malaria remains a major cause of preventable deaths among children worldwide, despite the availability of several interventions for controlling and eliminating the disease. The WHO recommended the first malaria vaccine, RTS, S/AS01 in October 2021 to immunize children in sub-Saharan Africa. In this study, we set out to evaluate the knowledge, awareness and acceptability of the malaria vaccine among mothers of under 5 in south-west Nigeria before the vaccine's rollout in Nigeria.
View Article and Find Full Text PDFInnovative public strategies in response to COVID-19: A review of practices from China.
Health Care Sci
December 2024
School of Healthcare Management, Tsinghua Medicine Tsinghua University Beijing China.
The COVID-19 pandemic presented unparalleled challenges to prompt and adaptive responses from nations worldwide. This review examines China's multifaceted approach to the crisis, focusing on five key areas of response: infrastructure and system design, medical care and treatment, disease prevention and control, economic and social resilience, and China's engagement in global health. This review demonstrates the effectiveness of a top-down command system at the national level, intersectoral coordination, a legal framework, and public social governance.
View Article and Find Full Text PDFLong-term multi-systemic complications following SARS-CoV-2 Omicron and Delta infection in children: a retrospective cohort study.
Clin Microbiol Infect
December 2024
National Centre for Infectious Diseases, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Ministry of Health, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Objectives: Most studies on long-term sequelae of SARS-CoV-2-infection in children were conducted pre-Omicron and pre-dated vaccination rollout. We examined long-term risk of new-incident multi-systemic sequelae after SARS-CoV-2 Delta/Omicron infection in a multi-ethnic Asian pediatric population.
Methods: Retrospective cohort study of Singaporean children aged 1- 17 years infected during Delta/Omicron BA.
"The COVID-19 pandemic in BRICS: Milestones, interventions, and molecular epidemiology".
PLOS Glob Public Health
December 2024
Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
Brazil, Russia, India, China, and South Africa (BRICS) are a group of developing countries with shared economic, healthcare, and scientific interests. These countries navigate multiple syndemics, and the COVID-19 pandemic placed severe strain on already burdened BRICS' healthcare systems, hampering effective pandemic interventions. Genomic surveillance and molecular epidemiology remain indispensable tools for facilitating informed pandemic intervention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!